Revelation Biosciences Inc (REVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.43M
Last updated: Nov 17, 2026 at 11:00 AM ET
Revelation Biosciences Inc (REVB) Stock Forecast
Analysts expect Revelation Biosciences (REVB) to earn -$33.98 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$16.52.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$33.98
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$16.52
- EPS consensus
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$33.98 | -$33.98 to -$33.98 | 1 |
| Dec 31, 2027 | -$16.52 | -$16.52 to -$16.52 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$6.20 | -$6.45 to -$5.86 | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$36.30.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$33.98 | -$36.30 | -$36.30 | -$36.30 | -$36.30 | N/A |
| Fiscal year ending Dec 31, 2027 | -$16.52 | -$20.23 | -$20.23 | -$20.23 | -$20.23 | N/A |
Frequently Asked Questions About REVB
What is the REVB stock forecast?
Consensus analyst estimates put Revelation Biosciences's EPS at -$33.98 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from REVB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$33.98, with estimates from -$33.98 to -$33.98 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$16.52, with estimates from -$16.52 to -$16.52 from 1 analyst.
How many analysts cover REVB?
1 analyst estimates EPS for Revelation Biosciences for the fiscal year ending Dec 31, 2026.
REVB pages: Overview, Earnings, Forecast, Financials, Competitors